Market Access News | pharmaphorum

News

Sanofi: NICE would reject Sarclisa even if it cost nothing

Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consid

News

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –

News

Sobi gets EU okay for long-acting haemophilia A drug

The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any

News

KalVista files first oral on-demand HAE drug with FDA

KalVista Pharma has filed its first marketing application to the US FDA, seeking approval for its oral plasma kallikrein inhibitor sebetralstat as an oral treatment for hereditary angioedem

News

FDA clears Roche digital pathology platform for diagnosis

Roche’s move into the digital pathology category has been boosted by FDA approval of a lab instrument and toolkit for use as an aid to clinical diagnosis.

News

FDA says yes to MSD’s 21-valent adult pneumococcal jab

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults.

Sanofi: NICE would reject Sarclisa even if it cost nothing

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

Sobi gets EU okay for long-acting haemophilia A drug

KalVista files first oral on-demand HAE drug with FDA

FDA clears Roche digital pathology platform for diagnosis

FDA says yes to MSD’s 21-valent adult pneumococcal jab

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks